Destiny Pharma #DEST – Developing Novel Medicines that Prevent Serious Infections. Alan Green talks to CEO Neil Clark

Two exciting late stage clinical assets – XF-73 and NTCD-M3 China Medical Systems – new XF-73 programme in China NTCD-M3 Phase 3 studies Spore COV – JV progress and Innovate funding Cash runway and upcoming value inflection points